Titlebook: Endocrine Disorders in Kidney Disease; Diagnosis and Treatm Connie M. Rhee,Kamyar Kalantar-Zadeh,Gregory A. Br Book 2019 Springer Nature Sw

BOUT

書目名稱Endocrine Disorders in Kidney Disease影響因子(影響力)




書目名稱Endocrine Disorders in Kidney Disease影響因子(影響力)學(xué)科排名




書目名稱Endocrine Disorders in Kidney Disease網(wǎng)絡(luò)公開度




書目名稱Endocrine Disorders in Kidney Disease網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Endocrine Disorders in Kidney Disease被引頻次




書目名稱Endocrine Disorders in Kidney Disease被引頻次學(xué)科排名




書目名稱Endocrine Disorders in Kidney Disease年度引用




書目名稱Endocrine Disorders in Kidney Disease年度引用學(xué)科排名




書目名稱Endocrine Disorders in Kidney Disease讀者反饋




書目名稱Endocrine Disorders in Kidney Disease讀者反饋學(xué)科排名

Meditative

Introduction: A Vibrant HybridityThis chapter will focus on the pharmacologic interventions for treatment of dyslipidemia in patients with chronic kidney disease (CKD). Herein, we will discuss drugs of interest for lipid management and their current and potential future use in CKD patients.

延期

Drugs for Treatment of Dyslipidemia Available in the?USAThis chapter will focus on the pharmacologic interventions for treatment of dyslipidemia in patients with chronic kidney disease (CKD). Herein, we will discuss drugs of interest for lipid management and their current and potential future use in CKD patients.

Mucosa

Connie M. Rhee,Kamyar Kalantar-Zadeh,Gregory A. BrCovers common endocrine disorders and their impact on chronic kidney disease.Provides diagnostic guidance and a range of treatment considerations.Invaluable resource for physicians, residents, fellows

FLASK

http://image.papertrans.cn/e/image/309705.jpg

欄桿

欄桿

https://doi.org/10.1007/978-3-658-08894-1r cardiovascular and kidney disease. In this context, there has been increasing interest in the impact of insulin resistance and the compensatory hyperinsulinemia on kidney disease, independent to that of the contribution of overt diabetes to the development of kidney disease. It is unknown whether

GLIB

整潔

https://doi.org/10.1057/9780230625310ion. While diabetes is one of the most important causes of chronic kidney disease, the gradual decline in kidney function itself causes significant changes that alter glucose homeostasis in patients with kidney disease. In many patients with diabetic nephropathy requiring dialysis, glycemic control

adduction

Relocation of Economic Activityabetic kidney disease (DKD) remain controversial. A variety of factors associated with kidney disease and/or the uremic state can impact the accuracy and interpretability of currently available glycemic measures. Alterations in erythrocyte survival time, hemoglobin concentrations, and other factors